Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012, Article ID 513865, 12 pages
Review Article

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria

Sandra A. Rotman Laboratories, McLaughlin-Rotman Centre for Global Health, Toronto General Hospital, University Health Network, 101 College Street, Suite 10-359, Toronto, ON, M5G 1L7, Canada

Received 7 January 2011; Accepted 28 February 2011

Academic Editor: Marion M. Chan

Copyright © 2012 Lena Serghides. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cerebral malaria is a severe complication of Plasmodium falciparum infection associated with high mortality even when highly effective antiparasitic therapy is used. Adjunctive therapies that modify the pathophysiological processes caused by malaria are a possible way to improve outcome. This review focuses on the utility of PPARγ agonists as an adjunctive therapy for the treatment of cerebral malaria. The current knowledge of PPARγ agonist use in malaria is summarized. Findings from experimental CNS injury and disease models that demonstrate the potential for PPARγ agonists as an adjunctive therapy for cerebral malaria are also discussed.